基于2例患者MiniPDX模型指导下的局部晚期喉癌个体化治疗初探  

A preliminary study on personalized treatment of locally advanced laryngeal cancer guided by MiniPDX models based on two patients

作　　者：任敬远[1,2] 鲍羿歧 王绪锐[1] 孙亚男[2] Ren Jingyuan;Bao Yiqi;Wang Xurui;Sun Yanan(Department of Head and Neck Surgery,Jilin Cancer Hospital,Changchun 130021,China;Department of Otorhinolaryngology Head and Neck Surgery,the Second Afiliated Hospital of Harbin Medical University,Harbin 150086,China)

机构地区：[1]吉林省肿瘤医院头颈外科,长春130021 [2]哈尔滨医科大学附属第二医院耳鼻咽喉头颈外科,哈尔滨150086

出　　处：《国际耳鼻咽喉头颈外科杂志》2024年第6期324-330,共7页International Journal of Otolaryngology-Head and Neck Surgery

基　　金：吉林省科技发展计划(20220505037ZP、20240404010ZP、20240302024GX);国家自然科学基青年基金(81402257)。

摘　　要：目的探讨利用人源微型异种移植(mini patient-derived xenograft,MiniPDX)模型指导喉癌患者的新辅助治疗方案以及保喉策略。方法利用上海立迪生物科技有限公司研发的OncoVee®MiniPDX系统,以喉癌患者标本为原型建立MiniPDX模型。在内镜下对喉癌组织进行活检,制备肿瘤细胞悬浮液装入中空纤维胶囊,通过皮下植入BALB/c-nu裸鼠背部进行药物敏感性试验。从MiniPDX测定中获得的最佳方案用于新辅助化疗和免疫治疗局部晚期喉癌。结果2022年3月至2023年6月,我们为2例局部晚期喉癌患者成功构建MiniPDX模型,建立个体化、敏感的药物筛选体系。MiniPDX模型为这2例患者确定潜在的有效药物,治疗后均达到临床缓解,1例患者达到完全缓解(complete response,CR),1例患者大部分缓解(partial response,PR)。2例患者均未出现严重不良反应,后续均成功保喉。结论建立喉癌MiniPDX模型指导下的个性化药物筛选体系,可能提高患者的临床效果,减少无效治疗,提高患者保喉率。Objective eExplore the use of the mini Patient-Derived Xenography(MiniPDX)to guide the newly-assisted therapy schemes of laryngeal cancer patients and laryngeal strategies.Methods Using the Oncovee MiniPDX system developed by Shanghai Lidi Biotechnology Co.,Ltd.,the MiniPDX model is established with the specimen of laryngeal cancer patients as a prototype.Under the endoscopy,the laryngeal cancer tissue is performed by biopsy,and then the tumor cell suspension is prepared into the hollow fiber capsule,and the back of the Balb/C-NU nude mice is implanted under the skin to perform drug sensitivity tests.The best solution obtained from the MiniPDX measurement is used for local advanced laryngeal cancer for local chemotherapy and immunotherapy.Results From March 2022 to June 2023,we successfully constructed the MiniPDX model for two local advanced throat cancer patients,and established an individualized and sensitive drug screening system.The MiniPDX model has determined potential effective drugs for these two patients.Both patients have reached clinical relief after treatment.One of the patients reached CR(complete response),and the other patient's big pr(PARTIAL response).Neither of the two patients had serious adverse reactions,and both patients successfully retained laryngeal function.Conclusions Establishing a personalized drug screening system guided by the laryngeal cancer MiniPDX model may improve the clinical effect of patients,reduce ineffective treatments,and increase the laryngeal function retention rate of patients.

关 键 词：喉肿瘤 化学疗法 MiniPDX模型 新辅助治疗 药物敏感度 

分 类 号：R739.65[医药卫生—肿瘤]